These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20692809)

  • 1. The use of clozapine among individuals with intellectual disability: a review.
    Singh AN; Matson JL; Hill BD; Pella RD; Cooper CL; Adkins AD
    Res Dev Disabil; 2010; 31(6):1135-41. PubMed ID: 20692809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of risperidone among individuals with mental retardation: clinically supported or not?
    Singh AN; Matson JL; Cooper CL; Dixon D; Sturmey P
    Res Dev Disabil; 2005; 26(3):203-18. PubMed ID: 15668072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities.
    de Leon J; Greenlee B; Barber J; Sabaawi M; Singh NN
    Res Dev Disabil; 2009; 30(4):613-69. PubMed ID: 19084370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: an overview.
    Matson JL; Neal D
    Res Dev Disabil; 2009; 30(3):572-86. PubMed ID: 18845418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological management of challenging behavior of individuals with intellectual disability.
    McGillivray JA; McCabe MP
    Res Dev Disabil; 2004; 25(6):523-37. PubMed ID: 15541630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone.
    Aman MG; Gharabawi GM;
    J Clin Psychiatry; 2004 Sep; 65(9):1197-210. PubMed ID: 15367046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for the use of clozapine in individuals with developmental disabilities.
    Sabaawi M; Singh NN; de Leon J
    Res Dev Disabil; 2006; 27(3):309-36. PubMed ID: 16040229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine, mental retardation, and severe psychiatric illness: clinical response in the first year.
    Rubin M; Langa A
    Harv Rev Psychiatry; 1995; 2(5):293-4. PubMed ID: 9384915
    [No Abstract]   [Full Text] [Related]  

  • 10. Psychiatric illness in mental retardation: an update on pharmacotherapy.
    Masi G; Luccherino L
    Panminerva Med; 1997 Dec; 39(4):299-304. PubMed ID: 9478071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine in China.
    Tang YL; Mao PX; Jiang F; Chen Q; Wang CY; Cai ZJ; Mitchell PB
    Pharmacopsychiatry; 2008 Jan; 41(1):1-9. PubMed ID: 18203045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine treatment of psychosis associated with velo-cardio-facial syndrome: benefits and risks.
    Gladston S; Clarke DJ
    J Intellect Disabil Res; 2005 Jul; 49(Pt 7):567-70. PubMed ID: 15966965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic withdrawal-induced relapse predicts future relapses in institutionalized adults with severe intellectual disability.
    Janowsky DS; Barnhill LJ; Khalid AS; Davis JM
    J Clin Psychopharmacol; 2008 Aug; 28(4):401-5. PubMed ID: 18626266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on clozapine treatment at the Charles Perrens Hospital in Bordeaux, 15 years after its marketing].
    Mercier C; Bret P; Bret MC; Queuille E
    Encephale; 2009 Sep; 35(4):321-9. PubMed ID: 19748368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?
    Tsiouris JA
    J Intellect Disabil Res; 2010 Jan; 54(1):1-16. PubMed ID: 20122096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reviewing the use of antipsychotic drugs in people with intellectual disability.
    La Malfa G; Lassi S; Bertelli M; Castellani A
    Hum Psychopharmacol; 2006 Mar; 21(2):73-89. PubMed ID: 16378330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
    Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational use and rationale for use: psychiatric medication at an Argentine institution for intellectual disability.
    de Menil V; Cohen A
    Transcult Psychiatry; 2009 Dec; 46(4):651-71. PubMed ID: 20028682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituting traditional antipsychotics with risperidone for individuals with mental retardation.
    Simon EW; Blubaugh KM; Pippidis M
    Ment Retard; 1996 Dec; 34(6):359-66. PubMed ID: 8990820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.